AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie income Tax Expense ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Earnings & Note 14 Income Taxes
Latest, FY2025
2,364
Period ended Dec 31, 2025
Change on a year earlier
-514.7%
-570 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Income Tax Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,364 | -514.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | -570 | -141.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 1,377 | -15.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 1,632 | +13.3% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 1,440 | -217.6% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | -1,224 | -325.0% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 544 | -211.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | -490 | -120.3% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 2,418 | +25.2% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 1,931 | +28.6% | Form 10-K (filed 2019-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 1,501 | – | Form 10-K (filed 2018-02-16) ↗ |
Breakdown
What makes up income tax expense ($m)
- Domestic Pre-Tax Earnings (Loss) [annual] ($M)-3,540 · FY2025
- Foreign Pre-Tax Earnings [annual] ($M)10,137 · FY2025
- Current Income Tax Expense [annual] ($M)2,856 · FY2025
- Deferred Income Tax Expense (Benefit) ($M)-492 · FY2025
- Cash Paid for Income Taxes [annual] ($M)3,626 · FY2025
- U.S. Federal Statutory Income Tax Rate [annual] (%)21.0% · FY2025
- Deferred Tax Assets, Net of Valuation Allowance [year-end] ($M)6,197 · FY2025
- Unrecognized Tax Benefits (UTB) — Ending Balance [year-end] ($M)4,505 · FY2025
Cite this data
StockData. (2026). AbbVie Income Tax Expense ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/tax_exp_tot
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.